妇科恶性肿瘤放化疗期间应用聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）的中国专家共识（2023年版）

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) during chemoradiotherapy for gynecological malignancies （2023 Edition）

摘要:

中性粒细胞减少症是妇科恶性肿瘤放化疗最常见的血液学毒性，可导致后续治疗延迟和剂量减少，并易引发中性粒细胞减少性发热及严重感染，影响患者预后。重视中性粒细胞减少症的危害，对其进行风险评估和规范性防治具有重要意义。聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）作为重组人粒细胞集落刺激因子（rhG-CSF）的长效制剂，可预防和治疗中性粒细胞减少症，临床使用便捷。为促进临床合理用药，本共识制定小组以循证证据为基础，评估其在妇科恶性肿瘤放化疗期间应用的有效性及安全性，明确预防与治疗的临床路径及给药方式，形成妇科恶性肿瘤放化疗期间应用PEG-rhG-CSF的中国专家共识。

Abstract:

Neutropenia is the most common hematologic toxicity of chemoradiotherapy for gynecological malignancies. It can lead to the delay and dose reduction of follow-up treatment, induce febrile neutropenia and severe infection easily, and affect the prognosis of patients. It is of great significance to pay attention to the harm of neutropenia and to carry out risk assessment and standardized prevention and treatment. The pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), as a long-acting preparation of recombinant human granulocyte colony-stimulating factor (rhG-CSF), can prevent and treat neutropenia and is convenient for clinical use. In order to promote clinical rational administration of drugs, based on evidence-based evidence, the consensus formulation team evaluated the efficacy and safety of its application during chemoradiotherapy for gynecological malignancies, defined the clinical pathway and administration mode of prevention and treatment, and then formed the Chinese expert consensus on the application of PEG-rhG-CSF during chemoradiotherapy for gynecological malignancies.